Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease—A Cohort Study
| Autor: | Jens Kjeldsen, Kenneth Grønkjær Madsen, Jesper Hallas, Anton Pottegård |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty IBD Overweight Antibodies Monoclonal Humanized Inflammatory bowel disease Gastroenterology Body Mass Index Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Immunology and Allergy Obesity Treatment Failure Proportional Hazards Models Retrospective Studies Anti-tumor necrosis factor-α agents Crohn's disease Tumor Necrosis Factor-alpha Proportional hazards model business.industry Body Weight Hazard ratio Adalimumab Retrospective cohort study Middle Aged Inflammatory Bowel Diseases medicine.disease Infliximab Ulcerative colitis 030220 oncology & carcinogenesis Cohort Female 030211 gastroenterology & hepatology medicine.symptom business Body mass index |
| Zdroj: | Madsen, K G, Pottegård, A, Hallas, J & Kjeldsen, J 2018, ' Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study ', Inflammatory Bowel Diseases, vol. 24, no. 12, pp. 2628–2633 . https://doi.org/10.1093/ibd/izy178 |
| ISSN: | 1536-4844 1078-0998 |
| Popis: | Background: In treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor-α agents (anti-TNF-α), obesity has been suspected as a cause of accelerated loss of response (LOR). We sought to determine whether overweight IBD patients have accelerated LOR when treated with anti-TNF-α agents, compared with normal weight IBD patients.Methods: We identified a cohort of adult IBD patients treated with anti-TNF-α agents at a Danish university hospital. Patients were grouped according to body mass index (BMI), and our main outcome was time to LOR. We performed survival analyses on LOR and calculated hazard ratios (HRs) with the normal weight group as the reference, while adjusting for confounders.Results: Of 210 eligible patients, 92 (44%) experienced LOR. One hundred eighty patients were treated with infliximab and 30 with adalimumab, 114 (54%) were normal weight, 51 (24%) were overweight, and 45 (21%) were obese. Regression analysis produced the following adjusted HRs, compared with the normal weight group: overweight 0.89 (95% confidence interval [CI], 0.51-1.56) and obese 1.31 (95% CI, 0.76-2.24), thus showing no statistically significant association between BMI and time to LOR. Subgroup analyses produced similar results, except for obese ulcerative colitis patients having an adjusted HR of 2.42 (95% CI, 1.03-5.70).Conclusions: In IBD patients treated with anti-TNF-α agents, we found no overall association between increased BMI and accelerated LOR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|